caa a22 4500 465738354 CHVBK 20180323111801.0 cr unu---uuuuu 170327e19900601xx s 000 0 eng 10.1007/BF02244140 doi (NATIONALLICENCE)springer-10.1007/BF02244140 Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia [Elektronische Daten] [D. Wiles, R. McCreadie, A. Whitehead] In a double-blind comparison of haloperidol decanoate and fluphenazine decanoate given 4-weekly for 60 weeks as maintenance therapy in 38 chronic schizophrenic in-patients, plasma haloperidol, fluphenazine and prolactin levels were measured at regular intervals by radioimmunoassay. After the first injection, the mean plasma haloperidol level was highest at week 1 and fell gradually towards week 4. Mean pre-dose haloperidol levels changed little after week 8. Results suggested an absorption half-life of 4 weeks, although, in three cases steady state was only achieved after 11 monthly injections. Steady state levels of both haloperidol and fluphenazine correlated highly with dose. In two subgroups observed at steady state, both drugs produced a biphasic pattern of plasma drug concentration between injections, a rapid rise on day 1 followed by stable elevated levels and a gradual return to pre-injection concentration by the end of week 4. In the fluphenazine subgroup there was a second peak on day 7 and a steeper decline, so that the mean area-under-curve in week 4 was 64% of that in week 1. Drug injections at steady state induced an increase in prolactin secretion in all of the fluphenazine sub-group and in half of those receiving haloperidol. Plasma prolactin changes resembled those for drug concentrations, but differences in times of peaks on day 1 resulted in weak correlations. Fluphenazine appeared more potent than haloperidol in provoking prolactin secretion. Springer-Verlag, 1990 Haloperidol decanoate nationallicence Fluphenazine decanoate nationallicence Prolactin nationallicence Human pharmacokinetics nationallicence Chronic schizophrenia nationallicence Wiles D. Department of Clinical Research, Crichton Royal Hospital, DG1 4TG, Dumfries, Scotland, UK aut McCreadie R. Department of Clinical Research, Crichton Royal Hospital, DG1 4TG, Dumfries, Scotland, UK aut Whitehead A. Janssen Pharmaceutical Limited, Grove, OX12 ODQ, Wantage, UK aut Psychopharmacology Springer-Verlag 101/2(1990-06-01), 274-281 0033-3158 101:2<274 1990 101 213 https://doi.org/10.1007/BF02244140 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02244140 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Wiles D. Department of Clinical Research, Crichton Royal Hospital, DG1 4TG, Dumfries, Scotland, UK aut NATIONALLICENCE 700 1- McCreadie R. Department of Clinical Research, Crichton Royal Hospital, DG1 4TG, Dumfries, Scotland, UK aut NATIONALLICENCE 700 1- Whitehead A. Janssen Pharmaceutical Limited, Grove, OX12 ODQ, Wantage, UK aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 101/2(1990-06-01), 274-281 0033-3158 101:2<274 1990 101 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer